covid-19 vaccination in india covid-19 vaccination in india india began administration of covid-19 vaccines on 16 january 2021. as of 4 march 2023, india has administered over 2.2 billion doses overall, including first, second and precautionary (booster) doses of the currently approved vaccines. in india, 95% of the eligible population (12+) has received at least one shot, and 88% of the eligible population (12+) is fully vaccinated. covid-19 vaccination programmeper capita fully vaccination map as of 22 january 2022date16 january 2021 (2021-01-16) – present (2 years, 117 days ago)location indiacausecovid-19 pandemic in indiatargetimmunisation of indians against covid-19budget₹35,000 crore (us$4.4 billion)organised bygovernment of indiaindian council of medical research state governments of indiaparticipants 1,025,789,302 people with one dose administered of covaxin or oxford–astrazeneca vaccine or sputnik v 952,033,158 people have been fully vaccinated with both doses of covaxin or oxford–astrazeneca vaccine or sputnik v or corbevax 228,593,024 people have been administered precautionary/booster doses of covaxin or oxford–astrazeneca vaccine or sputnik v or corbevax outcome 74% of the indian population has received one dose. 69% of the indian population has received both doses websitemohfwas on 4th march 2023 (07:00am) part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal india initially approved the oxford–astrazeneca vaccine (manufactured under license by serum institute of india under the trade name covishield) and covaxin (a vaccine developed locally by bharat biotech). they have since been joined by the sputnik v (manufactured under license by dr. reddy's laboratories, with additional production from serum institute of india being started in september), moderna vaccines, johnson & johnson vaccine and zycov-d (a vaccine locally developed by zydus cadila) and other vaccine candidates undergoing local clinical trials. according to a june 2022 study published in the lancet, covid-19 vaccination in india prevented an additional 4.2 million deaths from december 8, 2020, to december 8, 2021. vaccination programme cumulative doses administered across the country total doses administered across the country as of march 4, 2023 dose vaccination (percentage of eligible population vaccinated) partially vaccinated 1,025,789,302(94.61) fully vaccinated 952,033,158(87.81) precautionary(booster) dose 228,593,024 monthly graph of cumulative doses administered across the country graph of daily doses administered across the country graph of daily doses administered. last updated: march 4, 2023 daily vaccinations (1st dose only) daily vaccinations (2nd dose only) vaccine administration by gender vaccinations in india by gender as of march 4, 2023 gender vaccination male 1,00,60,86,799 female 96,74,31,679 others 4,80,887 vaccine administration by vaccine brand vaccinations in india by vaccine brand as of march 4, 2023 brand vaccination covishield 1,74,93,57,213 covaxin 36,37,74,435 sputnik v 12,32,692 corbevax 7,38,04,121 covovax 33,326 vaccine administration by age group vaccinations in india by age group as of march 4, 2023 age group vaccination 12-14 7,38,25,081 15-17 11,59,42,821 18-44 1,13,08,38,083 45-60 41,97,83,374 60+ 30,23,46,969 states by vaccine coverage (as of 15 september (7:00 ist)) number of vaccination centres sites conducting vaccination in india total-1,12,700• government — 1,10,000 • private — 2,700 source: cowin dashboard citizens above the age of 12 can book appointments through the cowin platform or can do a walk-in registration on site. all vaccine centres have registration desks, vaccine booths and observation rooms. vaccine certificates can be downloaded digitally through the cowin platform, or citizens can ask for a hard copy from vaccination centres. all government run vaccination centers provide free of cost vaccines, private centers do charge. background and timeline a vaccination centre in delhi. india's covid-19 vaccination deployment until 3 june first phase, initial approvals, launch of vaccination programme in september 2020, india's health minister harsh vardhan stated that the country planned to approve and begin distribution of a vaccine by the first quarter of 2021. the first recipients were to be 30 million health workers directly dealing with covid patients. a vial of covishield, the indian-manufactured version of the astrazeneca vaccine.a vial of covaxin vaccination drive for covid prevention in bhopal, india on 1 january 2021, the drug controller general of india (dcgi) approved emergency use of the oxford–astrazeneca vaccine (local trade name "covishield"). on 2 january, the dcgi also granted an interim emergency use authorisation to bbv152 (trade name "covaxin"), a domestic vaccine developed by bharat biotech in association with the indian council of medical research and national institute of virology. this approval was met with some concern, as the vaccine had not then completed phase 3 clinical trials. due to this status, those receiving covaxin were required to sign a consent form, while some states chose to relegate covaxin to a "buffer stock" and primarily distribute covishield. covid-19 vaccination roll out in aiims, new delhi, india on 16 january 2021 india began its vaccination programme on 16 january 2021, operating 3,006 vaccination centres on the onset. each vaccination centre will offer either covishield or covaxin, but not both. 165,714 people were vaccinated on the first day of availability. difficulties in uploading beneficiary lists at some sites caused delays. in the first three days, 631,417 people were vaccinated. of these, 0.18% reported side-effects and nine people (0.002%) were admitted to hospitals for observation and treatment. within those first days, there were concerns about low turnout, due to a combination of vaccine safety concerns, technical problems with the software used, and misinformation. the first phase of the rollout involved health workers and frontline workers, including police, paramilitary forces, sanitation workers, and disaster management volunteers. by 1 march, only 14 million healthcare and frontline workers had been vaccinated, falling short of the original goal of 30 million. second phase the next phase of the vaccine rollout covered all residents over the age of 60, residents between the ages of 45 and 60 with one or more qualifying comorbidities, and any health care or frontline worker that did not receive a dose during phase 1. online registration began on 1 march via the aarogya setu app and co-win ("winning over covid-19") website. amid the beginnings of a major second wave of infections in the country, vaccine exports were suspended in march 2021, and the government ordered 110 million covishield doses from sii. the company aims to produce 100 million doses per month, but by may 2021 its production capacity was only 60–70 million doses. following the conclusion of its trial, the dcgi issued a standard emergency use authorisation to covaxin on 11 march 2021. from 1 april, eligibility was extended to all residents over the age of 45. on 8 april, prime minister narendra modi called for a four-day teeka utsav ("vaccine festival") from 11 to 14 april, with a goal to increase the pace of the program by vaccinating as many eligible residents as possible. by the end of the utsav, india had reached a total of over 111 million vaccine doses to-date. third phase, sputnik v approval on 12 april, the dcgi approved russia's sputnik v vaccine for emergency use in india. a phase 3 trial was conducted in the country in september 2020, which showed 91.6% efficacy. the local distributor dr. reddy's laboratories stated that it planned to have the vaccine in india by late may 2021. on 19 april, it was announced that the next phase of the vaccination programme would begin on 1 may, extending eligibility to all residents over the age of 18. under phase 3, individual stakeholders were also given more flexibility in how they conduct the vaccination programme. as part of this plan, only half of the vaccines procured by the central drugs laboratory from manufacturers would be distributed by the central government. this supply would go to government-run clinics and be offered free-of-charge to residents 45 and over and priority workers and siphoned off to states based on factors such as the number of active cases and how quickly they are administering vaccines. the remainder would be offered to individual states and purchased on the open market (including private hospitals), which would be able to serve residents over the age of 18. registration for the next phase began on 28 april; a single-day record of nearly 13.3 million people registered. due to supply issues, several states, including delhi, gujarat and madhya pradesh announced that they would delay their wider rollouts of vaccines to later in the month. the initial shipment of 150,000 sputnik v doses arrived on 1 may, and began to be administered on 14 may. an estimated 156 million doses is expected between august and december; initially, doses will be sourced from russia, but domestic production is expected to begin by august 2021. on 13 may, the dcgi approved phase 2 and phase 3 trials of covaxin on children 2–18. on 14 may, health officials projected that based on the anticipated approval of additional vaccine options, it could receive at least 2.17 billion more vaccine doses from august to december 2021. on 25 may, india exceeded 200 million vaccine doses administered in total. on 3 june, the ministry of health and family welfare pre-ordered 300 million doses of a potential fourth vaccine, corbevax, which is undergoing phase 3 clinical trials. on 23 may, the union government allowed walk-in registrations for vaccination throughout the country; a health worker at the vaccination centre would register the recipient in the co-win vaccination database. the government claimed in an affidavit to the supreme court that as of june 23 about 78 per cent of vaccines had been administered via walk-in registration. return to centralised procurement on 31 may, an affidavit was issued in the supreme court of india requesting a review of the central government's vaccine distribution strategy, suggesting that the decision to only offer doses at no charge to priority workers and residents over the age of 45 was "prima facie arbitrary and irrational". on 7 june, prime minister modi announced that india would migrate back to centralised procurement of vaccines by 21 june. in an address, modi stated that multiple chief ministers had requested that the central government reconsider its new distribution strategy and reinstate the system it had used before may. as before, the centre will procure up to 75% of the country's vaccine supplies from manufacturers in bulk and distribute them to states at no